Trial Profile
An open, randomised, 2-periods crossover, single dose study evaluating the pharmacokinetics and pharmacodynamics of follicle-stimulating hormone after single subcutaneous dose of highly purified urofollitrophin (hp-FSH; Fostimon- IBSA) in healthy fertile women
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Apr 2017
Price :
$35
*
At a glance
- Drugs Urofollitropin (Primary)
- Indications Female infertility
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors IBSA
- 04 Apr 2017 New trial record